BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li JY, Quan ZW, Zhang Q, Liu JW. The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma. BMC Cancer. 2007;7:125. [PMID: 17617924 DOI: 10.1186/1471-2407-7-125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Tao J, Xu XS, Song YZ, Qu K, Wu QF, Wang RT, Meng FD, Wei JC, Dong SB, Zhang YL, Tai MH, Dong YF, Wang L, Liu C. Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescence. World J Gastroenterol 2014; 20(28): 9497-9505 [PMID: 25071344 DOI: 10.3748/wjg.v20.i28.9497] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
2 Quan ZW, Yang Y, Li JY, Gong W, Qin YY, Li SG. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Biomed Pharmacother. 2010;64:451-457. [PMID: 20359855 DOI: 10.1016/j.biopha.2010.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]